Showing results (31-40 of 57) with videos related to
Sort By:
Pageof 6
Cancer Cell International|June 27, 2017
<i>HOTAIR</i>: a key regulator in gynecologic cancersJing Li, Jing Wang, Yan Zhong, et al.Discover Oncology|September 29, 2025
Low pre-treatment neutrophil-to-lymphocyte ratio predicted a better survival in recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitorsJing Li, Yulu Wang, Jiayu Pei, et al.Heliyon|January 9, 2023
A novel prognostic model to predict OS and DFS of stage II/III gastric adenocarcinoma patients in ChinaJing Li, Hejun Liang, Xiaonan Xue, et al.Oncology Letters|February 20, 2013
The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cellsShaoru Li, Yan Li, Ruili Hu, et al.Future Oncology (London, England)|November 4, 2016
Deregulated miRNAs in human cervical cancer: functional importance and potential clinical useJing Li, Qiuli Liu, Leslie H Clark, et al.Future Oncology (London, England)|October 4, 2016
HOTAIR rs920778 polymorphism is associated with ovarian cancer susceptibility and poor prognosis in a Chinese populationHaifeng Qiu, Xiujuan Wang, Ruixia Guo, et al.Experimental Biology and Medicine (Maywood, N.J.)|May 28, 2020
Buformin increases radiosensitivity in cervical cancer cells via cell-cycle arrest and delayed DNA-damage repairLing Chen, Ting Zhang, Qiuli Liu, et al.Advanced Healthcare Materials|August 14, 2025
In Situ Formed Nanocomposite Hydrogel Improve Local Delivery of Antiangiogenic Agents and Immune Checkpoint Inhibitor for Cervical Carcinoma TherapyJing Li, Cuixia Zheng, Lei Zhang, et al.Investigational New Drugs|June 7, 2018
The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancerMei Tang, Qiuli Liu, Leyuan Zhou, et al.Heliyon|September 23, 2024
Efficacy of PD-1/PD-L1 blockade immunotherapy in recurrent/metastatic high-grade neuroendocrine carcinoma of the cervix: A retrospective studyHaifeng Qiu, Min Wang, Dian Wang, et al.Pageof 6